Abstract
Pancreatic carcinoma is still a challenging disease, although the resection rate and the operative safety have been improved, the prognosis of the patients is dismal. Now the therapy strategy is changed from surgery firstinto the mode of multidisciplinary team (MDT). Surgical resection is the only curable therapy for pancreatic carcinoma. Recently, the clinical role of extent of lymphadenectomy, combined vascular resection, and total mesopancreas excision was recognized more deeply. If 1 mm ruleis applied to define the resection margin, most pancreatic cancer resections are R1 resections, which benefit the patients. There has been consensus on the definition of perioperative complications. Neoadjuvant therapy is advocated for patients with borderline resectable pancreatic carcinoma. Key words: Pancreatic neoplasms; Surgical therapy; Neoadjuvant therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
